Zelluna ASA
Zelluna ASA develops T-cell receptor (TCR) cellular immunotherapy products for the treatment of solid cancers. The company has a clinical partnership with Medpace Holdings, Inc. to support the clinical trial of ZI-MA4-1 (ZIMA-101); and collaboration with Etcembly Ltd for AI-enabled TCR engineering. The company was founded in 2016 and is based in Oslo, Norway.
Zelluna ASA (ZLNA) - Total Liabilities
Latest total liabilities as of December 2025: Nkr17.65 Million NOK
Based on the latest financial reports, Zelluna ASA (ZLNA) has total liabilities worth Nkr17.65 Million NOK as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Zelluna ASA - Total Liabilities Trend (2021–2025)
This chart illustrates how Zelluna ASA's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Zelluna ASA Competitors by Total Liabilities
The table below lists competitors of Zelluna ASA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Goal Acquisitions Corp
PINK:PUCK
|
USA | $15.79 Million |
|
Fleming Properties AB
ST:FLMNG
|
Sweden | Skr59.39 Million |
|
Tamawood Ltd
AU:TWD
|
Australia | AU$18.85 Million |
|
Ege Seramik Sanayi ve Ticaret AS
IS:EGSER
|
Turkey | TL4.75 Billion |
|
Taiwan Advance Bio-Pharmaceutical Inc.
TWO:4186
|
Taiwan | NT$439.78 Million |
|
Samchuly Bicycle Co. Ltd
KQ:024950
|
Korea | ₩141.49 Billion |
|
TOUBF
PINK:TOUBF
|
USA | $748.64K |
Liability Composition Analysis (2021–2025)
This chart breaks down Zelluna ASA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 4.44 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zelluna ASA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zelluna ASA (2021–2025)
The table below shows the annual total liabilities of Zelluna ASA from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Nkr17.65 Million | -46.84% |
| 2024-12-31 | Nkr33.19 Million | -52.34% |
| 2023-12-31 | Nkr69.65 Million | +15.46% |
| 2022-12-31 | Nkr60.32 Million | -3.31% |
| 2021-12-31 | Nkr62.38 Million | -- |